scholarly journals Current pharmacological treatment of heart failure: What is new in the 2021 ESC guidelines?

2021 ◽  
Vol 0 (Ahead of Print) ◽  
Author(s):  
Adam Stanczyk ◽  
Norbert Barlicki
2008 ◽  
Vol 7 ◽  
pp. 23-23
Author(s):  
T RYWIK ◽  
P KOLODZIEJ ◽  
R TARGONSKI ◽  
M MICHALSKI ◽  
M FEDYKLUKASIK ◽  
...  
Keyword(s):  

2017 ◽  
pp. 101-106
Author(s):  
Thi Thanh Hien Bui ◽  
Hieu Nhan Dinh ◽  
Anh Tien Hoang

Background: Despite of considerable advances in its diagnosis and management, heart failure remains an unsettled problem and life threatening. Heart failure with a growing prevalence represents a burden to healthcare system, responsible for deterioration of patient’s daily activities. Galectin-3 is a new cardiac biomarker in prognosis for heart failure. Serum galectin-3 has some relation to heart failure NYHA classification, acute coronary syndrome and clinical outcome. Level of serum galectin-3 give information for prognosis and help risk stratifications in patient with heart failure, so intensive therapeutics can be approached to patients with high risk. Objective: To examine plasma galectin-3 level in hospitalized heart failure patients, investigate the relationship between galectin-3 level with associated diseases, clinical conditions and disease progression in hospital. Methodology: Cross sectional study. Result: 20 patients with severe heart failure as NYHA classification were diagnosed by The ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure (2012) and performed blood test for serum galectin-3 level. Increasing of serum galectin-3 level have seen in all patients, mean value is 36.5 (13.7 – 74.0), especially high level in patient with acute coronary syndrome and patients with severe chronic kidney disease. There are five patients dead. Conclusion: Serum galectin-3 level increase in patients with heart failure and has some relation to NYHA classification, acute coronary syndrome. However, level of serum galectin-3 can be affected by severe chronic kidney disease, more research is needed on this aspect Key words: Serum galectin-3, heart failure, ESC Guidelines, NYHA


2019 ◽  
Vol 73 (21) ◽  
pp. 2756-2768 ◽  
Author(s):  
Peter van der Meer ◽  
Hanna K. Gaggin ◽  
G. William Dec
Keyword(s):  

2017 ◽  
Vol 4 (2) ◽  
pp. 99-104 ◽  
Author(s):  
Benoit Delepaul ◽  
Guillaume Robin ◽  
Clément Delmas ◽  
Thomas Moine ◽  
Adrien Blanc ◽  
...  
Keyword(s):  

ESC CardioMed ◽  
2018 ◽  
pp. 1863-1867
Author(s):  
Michel Komajda

Ivabradine slows down the heart rate through a blockade of the funny current channels in the sinoatrial node cells. The efficacy of the drug was tested in a large outcome clinical trial in stable chronic heart failure with reduced ejection fraction, in sinus rhythm, on a contemporary background therapy including beta blockers.


Sign in / Sign up

Export Citation Format

Share Document